- RecruitingPHASE2, PHASE3
Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial
This study, called MND-SMART, is testing different medicines to see if they can slow down Motor Neurone Disease (MND) and help people live longer. It's designed to be flexible, quickly adding new promising drugs and removing those that don't help.
For: Motor Neuron Disease, Amyotrophic Lateral SclerosisUnited Kingdom - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 study to assess the efficacy and safety of 2 dosage regimens of oral fidrisertib (IPN60130) for the treatment of fibrodysplasia ossificans progressiva in male and female paediatric and adult participants.
This study is testing a new medicine, fidrisertib, for children and adults with Fibrodysplasia Ossificans Progressiva (FOP). We want to see if it can slow down the new bone growth and reduce flare-ups, and if it's safe to use. Some participants will receive a dummy pill (placebo).
For: Fibrodysplasia Ossificans ProgressivaSweden · Germany · France - Not yet recruitingPHASE1
Progesterone and Muscle Protein Synthesis in Premenopausal Women (MP4-MPS)
This study looks at how the hormone progesterone affects muscle growth in healthy young women. Researchers want to see if progesterone changes how muscles respond to exercise compared to a dummy pill. It involves taking pills, exercising one leg, and giving blood and small muscle samples.
For: Healthy Volunteers · Female · ProgesteroneCanada - Active not recruitingPHASE4
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
This study looks at two different doses of a drug called cabozantinib for a type of thyroid cancer called medullary thyroid cancer (MTC) that has spread and is getting worse. We want to see if a lower dose works just as well with fewer side effects.
For: Medullary Thyroid CancerAustralia · Canada · Croatia - Active not recruitingPHASE3
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
This study looks at how safe and effective two medicines, fingolimod and interferon beta-1a, are for young people aged 10-17 with multiple sclerosis (MS). It compares them to see which works best and is safest.
For: Multiple SclerosisUnited States · Australia · Austria